KBC Group’s Denali Therapeutics DNLI Stock Holding History

KBC Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$102K	Hold	4,943	–	–	﹤0.01%	1370
2026 Q2	$127K	Hold	4,943	–	–	﹤0.01%	1273
2026 Q1	$95K	Sell	4,943 -1,325	-21%	-$26.4K	﹤0.01%	1346
2025 Q4	$103K	Buy	6,268 +1,773	+39%	+$29.9K	﹤0.01%	1251
2025 Q3	$65K	Hold	4,495	–	–	﹤0.01%	1533
2025 Q2	$63K	Sell	4,495 -1,955	-30%	-$27.5K	﹤0.01%	1476
2025 Q1	$88K	Buy	6,450 +116	+2%	+$2.22K	﹤0.01%	1551
2024 Q4	$129K	Buy	6,334 +2,731	+76%	+$69.9K	﹤0.01%	1382
2024 Q3	$105K	Hold	3,603	–	–	﹤0.01%	1251
2024 Q2	$84K	Buy	3,603 +1,138	+46%	+$21.8K	﹤0.01%	1272
2024 Q1	$51K	Hold	2,465	–	–	﹤0.01%	1546
2023 Q4	$53K	Hold	2,465	–	–	﹤0.01%	1482
2023 Q3	$51K	Buy	+2,465	New	+$62.5K	﹤0.01%	1428

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

KBC Group's DNLI Position: Q3 2026 in Review

KBC Group held its Denali Therapeutics (DNLI) position steady in Q3 2026 at 4,943 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

KBC Group first reported a position in DNLI in Q3 2023 and has held it in 13 quarters since. The position peaked at $129K in Q4 2024. 140 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

KBC Group held 4,943 shares of Denali Therapeutics worth $102K as of Q3 2026.
KBC Group left its Denali Therapeutics share count unchanged in Q3 2026.
Denali Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1370 holding.
KBC Group first reported a position in Denali Therapeutics in Q3 2023 and has held it in 13 quarters since.
KBC Group's Denali Therapeutics position peaked at $129K in Q4 2024.
140 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.